EphB3-targeted regulation of miR-149 in the migration and invasion of human colonic carcinoma HCT116 and SW620 cells

Guodong Zhang,1,6 Xiaozhuo Liu,2,6 Yinfeng Li,2 Yan Wang,3 Huankun Liang,4 Kangyan Li,4 Laiqing Li,4 Cuicui Chen,4 Wenqiao Sun,5 Shoulei Ren,7 Pengfei Zhu3 and Licheng Zhang5

1Department of Medical Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong; 2School of Light Industry Engineering, Guizhou Institute of Technology, Guiyang, Guizhou; 3Shandong Medicine Technician College, Tai’an, Shandong; 4Guangzhou Youdi Biotechnology Company, Guangzhou, Guangdong; 5Cancer Center of The 88 Hospital of People’s Liberation Army, Tai’an, Shandong, China.

Key words
EphB3, human colorectal cell, invasion, migration, miR-149

Correspondence
Licheng Zhang, Cancer Center of the 88 Hospital of People’s Liberation Army, 271000 Tai’an, Shandong, China. Tel: +86-020-2205-6980; Fax: +86-020-2205-6980; E-mail: zhang88cn@sohu.com

Guodong Zhang, Department of Medical Oncology, Cancer Center of Guangzhou Medical University, Guangzhou, Guangdong, China. Tel: +86-020-6667-3657; Fax: +86-020-6667-3657; E-mail: zgdddoctor@sina.cn

5Equal contributors.

Funding Information
Guangdong Province Science and Technology Plan Projects (20150119); Chinese National Foundation of National Science Grants (81402501).

Received July 28, 2016; Revised December 28, 2016; Accepted December 30, 2016.

Cancer Sci 108 (2017) 408–418
doi: 10.1111/cas.13161

Although the morbidity and mortality rates have declined in some western countries, this rate has remained elevated in China and other developing countries in past decades.8–10 Screening for CRC allows the early diagnosis of the malignancy and reduces the mortality of this disease.

Recent studies have suggested that miR-149 may play an important role in various cancer diseases. miR-149 has been shown to function as both a tumor suppressor and an oncogene in the development of multiple types of solid tumors.11,12 Ectopic expression of miR-149 induces apoptosis of neuroblastoma cells. Loss of miR-149 leads to some oncogenes gain of function in renal cell carcinoma and prostate carcinoma.13,14 Elevated expression of miR-149 has been reported to be important in the progression of nasopharyngeal carcinoma.15 However, the expression pattern and role of miR-149 in the development of CRC remains unclear.

In this study, we examined miR-149 expression pattern in CRC cells and tissue samples, and investigated the function of miR-149 in cell proliferation, migration, and invasion of CRC cells. We also identified EphB3 as a target gene for miRNAs.
miR-149 using luciferase reporter assay. Moreover, experiments in vitro showed that knockdown expression of EphB3 could suppress cell proliferation and invasion, and ectopic expression of EphB3 restored the phenotypes of CRC cell lines transfected with miR149. In addition, silencing of EphB3 significantly affected cell cycle progression distribution and increased apoptosis in CRC cell lines. Finally, in vivo results demonstrated that knockdown of EphB3 by siRNA inhibited tumor growth. Our results indicated that miR-149 might act as a tumor suppressor and served as a potential therapeutic target in CRC.

Materials and Methods

Cell culture. The human CRC cell lines HCT116, SW620 and normal colon epithelial NCM460 cell were cultured at 37°C in a 5% CO2 atmosphere and maintained in DMEM containing 10% FBS and 2 mM l-glutamine (Invitrogen, Los Angeles, CA, USA).

Patient samples. A total of 30 pairs of primary CRCs and their paired noncancerous colonic tissues were collected from Cancer Center of The 88 Hospital of People’s Liberation Army. All patients provided written informed consent for the use of their tissues. This study was approved by the Institutional Review Board of The 88 Hospital of People’s Liberation Army, and all participants gave written informed consent. All tissues had been histologically confirmed to be an adenocarcinoma of the colon. Tissue samples were collected, snap-frozen in liquid nitrogen, and stored at −80°C until further analysis.

Real-time RT-PCR. Total RNA was extracted from CRC cells and tumor tissues by using TRIZOL Reagent (Invitrogen). The cDNA Synthesis Kit (Takara, Tokyo, Japan) was used for the synthesis of cDNA according to the manufacturer’s instructions. Quantitative RT-PCR was performed to detect the expression levels of miRNA and mRNA. Quantitative PCR was accomplished to detect the expression levels of miRNA and mRNA using the Light Cycler 480 detection system (Roche Diagnostics, Indianapolis, IN, USA) and interaction dye SYBR Green. U6 snRNA and actin mRNA levels were used for normalization. Primer sequences were listed in Table 1. The quantitative RT-PCR results were analyzed and expressed as relative miRNA or mRNA levels of the Ct value, which was then converted to fold change.

Western blot analysis. Total proteins were prepared from the CRC cells. The protein concentration was determined using Bio-Rad protein assay system (Bio-Rad, Hercules, CA, USA). Proteins were analyzed with SDS polyacrylamide gel electrophoresis. After electrophoresis, they were electro-transferred to the PVDF membrane. The membrane containing the proteins was used for immunoblotting with appropriate antibodies. The protein bands were scanned and quantified.

Transfection of miRNA mimics, siRNAs or plasmid vectors. The human miR-149 duplex mimic and negative control oligonucleotide duplex mimic (miR-NC) were designed and provided by Ribobio (Guangzhou, China). The small interfering RNA

| Gene     | Name                | Primers (5’ to 3’)                                                                 |
|----------|---------------------|------------------------------------------------------------------------------------|
| hsa-miR-149 | miR-149-RT          | GTCTATCCAAGTGCAGGGTCCAGAGTTAACCTGACTGATAACAGGAGAGT                                 |
|          | miR-149-F           | GGTCTGCTCCGTGGCTCTTTGTT                                                         |
|          | miR-149-R           | CAAGTGCAGGGTCCAGAGTTAACCTG                                                       |
| U6       | U6-RT               | GTCTATCCAAGTGCAGGGTCCAGAGTTAACCTGACTGATAACAGGAGAGT                                 |
|          | U6-F                | CAAATTCGTGAAGCGTTCCATA                                                          |
|          | U6-R                | AGTGCAGGGTCCAGAGTTAACCTG                                                       |
| EphB3    | EphB3-F             | CCGTGATCCCAACACAGGTCC                                                         |
|          | EphB3-R             | CTCGAGCCGGATTATATTGG                                                              |
| β-actin  | β-actin-F           | CGTGACGCCCAACACAGGTCC                                                         |
|          | β-actin-R           |ATACCTCTGGTCTGTCGTATCC                                                                 |
| Caspase-3 | Caspase-3-F         | GTATGCACTACCTCACCAGCAC                                                        |
|          | Caspase-3-R         | GCTGACCCCTTGGTTAAC                                                                 |
| Caspase-6 | Caspase-6-F         | CATGACAGAAACAGATGC                                                            |
|          | Caspase-6-R         | GTGACAGAAACAGATGC                                                            |
| Bax      | Bax-F               | CTGAGCGAGGTCTCACCAGAGG                                                          |
|          | Bax-R               | AGTACGGAAGGTCTCACCAGAGG                                                          |
| Bcl-2    | Bcl-2-F             | CGAGATGTCACGCCAGCAGG                                                          |
|          | Bcl-2-R             | GATCCAGGTGTGACAGG                                                              |

Table 2. Primers used for cell transfection and luciferase reporter vector construction. Primers were designed using Primer 5.0 software

| Gene     | Name                      | Primers (5’ to 3’)                                                                 |
|----------|---------------------------|------------------------------------------------------------------------------------|
| miR-149  | miR-149 mimics            | UCGGUCUCCUGGCUCUUCACUCC                                                          |
| mimics-NC | miR-149 mimics            | GGGAGUGUAGAACAGCCGAGGAGCCA                                                     |
| SiEphB3  | SiEphB3-sense              | GACCCUAAGAGGCGUU                                                                  |
|          | SiEphB3-antisense          | AACAGCCCUAUAGGGGCUU                                                              |
| SiRNA-NC | SiRNA control-sense        | GAAAGAUCGAGUUCGCCGUU                                                             |
|          | SiRNA antisense            | ACGCGGCGACUAGAUACC                                                                |
| EphyB3   | EphB3-luc-F               | GCCGTCCAGACGAGGAGGCCAGGAGG                                                     |
|          | EphB3-luc-R               | AAAGAATGCGAGGCCCATTTGAGGTCCTTATC                                               |
Fig. 1. Expression level of miR-149 in human CRC cell lines and clinical tumor tissues. (a) Expression of miR-149 in human CRC cell lines relative to the normal human colon epithelial cell line NCM460. Data are the mean ± SEM (n = 3), each bar represents the mean of three independent experiments carried out in triplicate. **P < 0.01, compared with NCM460 group. (b) The relative miR-149 expression between tumor tissues and their paired adjacent colonic normal tissues from 30 CRC patients using real-time PCR. **P < 0.01, compared with normal group.

Fig. 2. Ectopic expression of miR-149 inhibits CRC cell proliferation and invasion in vitro. (a) The level of miR-149 expression in HCT116 and SW620 cells increased significantly after transfection with 150 nM miR-149 mimics compared with the negative control. (b) Transfection of cells with miR-149 mimics inhibited cell growth at the indicated time points compared with cells transfected with negative control. (c, d) Colony formation assay of HCT116 and SW620 cells transfected with the miR-149 mimics or negative control. (e, f) Transwell assay showed that miR-149 overexpression inhibited invasion in HCT116 and SW620 cells. Data are the mean ± SEM (n = 3), each bar represents the mean of three independent experiments carried out in triplicate. *P < 0.05, compared with control group. **P < 0.01, compared with control group.
siRNA) for EphB3 and the negative control RNA (siRNA-NC) were synthesized and purified by Gene Pharma (Shanghai, China). The sequences of miRNAs and siRNAs were described in Table 2. The open reading frame of EphB3 (NM_004443) that was generated by PCR was then inserted into the pEGFP-C1 expression vector which was named pEGFP/EphB3. The recombinant vector was confirmed by the digestion analysis of restriction endonuclease and DNA sequencing. Cultured HCT116 and SW620 cells were transfected with miRNAs, siRNAs or plasmid vectors with the Lipofectamine 2000 reagent (Invitrogen) following the manufacturer’s protocol.

Cell proliferation, migration and invasion assays. For cell proliferation assay, cell viability was determined by the MTT method. Briefly, CRC cells were transfected with 150 nM miR-149 mimics or 100 nM siRNA-EphB3. Twenty-four hours later, cells were seeded in 96-well plates at a density of $1 \times 10^4$ cells/well. Then, 20 µL MTT (5 mg/mL) was added to each well and incubated for 4 h. The medium was then removed, and the formazan crystals were dissolved with dimethylsulfoxide (DMSO). Absorbance was read at 570 nm on a microplate reader (Multiskan Spectrum; Thermo Fisher, Waltham, MA, USA).

For cell migration and invasion assay, uncoated or matrigel coated transwells (BD Biosciences, Franklin, NJ, USA) containing 8 µm pores were used (BD Biosciences, Mountain View, CA, USA). Cells transfected with 150 nM miR-149 mimics or 100 nM siRNA-EphB3 were seeded into the upper chamber in serum-free DMEM. Cells were fixed in 100% methanol 72 h later and stained with a 1:5 dilution of Giemsa (Sigma, San Francisco, CA, USA) for 40 min at room temperature. Cells remaining on the upper side of the filter were removed with a cotton swab. The filters were then mounted onto slides and images were taken at 10× magnification. From these images, the number of migratory or invasive cells was counted.

Vector constructs and luciferase reporter assay. To construct EphB3 3'UTR plasmid, the full-length 3'UTR of human EphB3 mRNA (NM_004443) containing the putative miR-149 binding sequence was cloned into the pGL3 promoter vector (Promega, Madison, WI, USA) (Fig. S1). The putative miR-149 recognition sites in the EphB3 3'UTR were mutated by site-directed mutagenesis. Cells transfected with 150 nM miR-149 mimics plus vector containing the wild-type EphB3 3'UTR versus the other three groups.

---

**Fig. 3.** EphB3 is a direct target gene of miR-149 in CRC cells. (a) qRT-PCR analysis of EphB3 mRNA in cells transfected with miR-149 mimics or a negative control. **P < 0.01, miR-149 mimics versus the respective negative control groups.** (b, c) Western blots analysis of EphB3 in CRC cells transfected with miR-149 mimics. **P < 0.01, miR-149 mimics versus the respective negative control groups.** (d) Base pairing comparison between the mature miR-149 and the wt or mutant target site in the 3'UTR of EphB3 mRNA. (e) The luciferase activity of various reporters in the presence or absence of miR-149 mimics in SW620 cells. Data are the mean ± SEM (n = 3), each bar represents the mean of three independent experiments carried out in triplicate. **P < 0.01, miR-149 mimics plus vector containing the wild-type EphB3 3'UTR versus the other three groups.
mutagenesis. For the dual luciferase assay, CRC cells were transfected with 150 nM of pre-miR-149, or a negative precursor control using Lipofectamine 2000 (Invitrogen). After 24 h, cells were co-transfected with 200 ng of pRL-EphB3 and 100 ng of pGL3-luc as the internal control. Cell extracts were prepared 48 h later and the dual luciferase reporter assay (Promega) was performed according to the manufacturer’s protocol.

Cell cycle assay. Cell cycle assay was performed by flow cytometry. After transfected with 100 nM siRNA-EphB3 or siRNA control, CRC cells were harvested, washed twice using PBS, and fixed in 70% ethanol at 4°C overnight. Then cells were incubated with propidium iodide at room temperature for 1 h and were analyzed by flow cytometry using a FACScan flow cytometer (BD Biosciences).

Cell apoptosis assay. Apoptotic cells can be recognized and distinguished from normal cells using an Annexin V-FITC/PI apoptosis kit for flow cytometry according to the manufacturer’s instructions (Invitrogen). After transfected with
Fig. 5. Ectopic expression of EphB3 restores the phenotypes of CRC cell lines transfected with miR149. (a) qRT-PCR analysis of EphB3 mRNA in CRC cells after ectopic expression of EphB3. Data are the mean ± SEM (n = 3), each bar represents the mean of three independent experiments carried out in triplicate. **P < 0.01, miR-149 mimics + pEGFP/EphB3 group versus miR-149 mimics group. (b, c) Western blots analysis of EphB3 expression in CRC cells after ectopic expression of EphB3. Data are the mean ± SEM (n = 3), each bar represents the mean of three independent experiments carried out in triplicate. **P < 0.01, miR-149 mimics + pEGFP/EphB3 group versus miR-149 mimics group. (d) MTT analysis of growth in CRC cells after ectopic expression of EphB3. (e–h) Ectopic expression of EphB3 could rescue the capacity of decreased invasiveness in CRC cells induced by miR-149 mimics. Data are the mean ± SEM (n = 3), each bar represents the mean of three independent experiments carried out in triplicate. **P < 0.01, miR-149 mimics + pEGFP/EphB3 group versus miR-149 mimics group.
100 nM siRNA-EphB3 or siRNA control, CRC cells were harvested and washed twice with cold PBS, and then incubated with 5 μL FITC-Annexin V and 1 μL PI working solution (100 μg/mL) for 15 min in the dark at room temperature. Cellular fluorescence was measured by flow cytometry analysis. (17)

In vivo xenograft experiments. Female BALB/C nude mice at the age of 4 weeks were randomly divided into two groups (five mice per group). Has-miR-149 or miR-control stable transfection HCT 116 and SW620 cells suspensions (1 × 10⁶ cells/mL) in 200 μL serum-free medium were subcutaneously injected into the flanks of nude mice, respectively. Tumor growth was examined twice per week for 4 weeks. After 4 weeks, tumor samples were carefully removed and weighed.

Statistical analyses. The data were analyzed by one-way analysis of variance and the Student’s t-test to determine statistical significance using SPSS 16.0 statistic software (SPSS, Armonk, NY, USA). Each experiment was repeated at least three times. The results were expressed as mean ± SEM. Outcomes were considered statistically significant with two-tailed P < 0.05.

Results

miR-149 expression patterns in CRC cells and clinical samples. To assess the role of miR-149 in colorectal cancer, we used quantitative RT-PCR to measure the expression of miR-149 in CRC cell lines and tumor tissues. We found that miR-149 was significantly decreased in HCT116 and SW620 cell lines compared to the normal human colon epithelial NCM460 cell line (Fig. 1a) and colonic tissues compared to the noncancerous colonic tissues (Fig. 1b).

Ectopic expression of miR-149 inhibits CRC cells proliferation and invasion in vitro. To investigate the role of miR-149 in CRC cells, HCT116 and SW620 cells were transiently transfected with either miR-149 mimics or miR-149 mimics control (Fig. S2). Quantitative RT-PCR results showed that miR-149 mimics could significantly upregulate the expression of miR-149 in HCT116 and SW620 cells at the fifth day post-transfection (Fig. 2a) compared to miR-149 mimics control. HCT116 and SW620 cells transfected with miR-149 mimics showed significantly lower levels of cell proliferation than the mimics control groups as determined by MTT assay (Fig. 2b). Colony-formation assay demonstrated that overexpression of miR-149 significantly reduced both the number of colonies formed and the size of the colonies after 15 days of culture compared with the negative control in HCT116 and SW620 cell lines (Fig. 2c, d). In addition, transwell assays indicated that the invasive capacity of HCT116 and SW620 cells over-expressing miR-149 were significantly reduced compared with the negative control (Fig. 2e, f).

EphB3 is a direct target gene of miR-149 in CRC cells. First, we investigated the targets of miR-149 used the miRecords resource to obtain potential targets of miR-149 from three independent prediction tools included on the website. Among
the putative targets of miR-149, we chose EphB3 for further analysis, because it had been previously implicated in promoting colorectal cancer progression, and seven potential binding sites of miR-149 in the EphB3 3' UTR by in silico analysis. Then, EphB3 expression level was analyzed in HCT116 and SW620 cell lines after transfection with either miR-149 mimics or mimic-NC sequences. Indeed, real-time PCR and western blot analyses confirmed this prediction. Briefly, after transient transfection of miR-149 mimics into HCT116 and SW620 cells EphB3 mRNA (Fig. 3a) and protein levels (Fig. 3b,c) were significantly suppressed compared with negative control.

To obtain further direct evidence that EphB3 is a target of miR-149, we characterized the binding site of miR-149 in the 3' UTR of EphB3 mRNA (Fig. 3d). The data demonstrated that miR-149 but not miR149-control RNA specifically decreased the luciferase activity. The mutant reporter co-transfected with miR-149 did not show significant decrease in the relative luciferase activity compared with negative control RNA (Fig. 3e).

Taken together, these data suggest that EphB3 is a direct target gene of miR-149 in CRC cells.

Silencing of EphB3 significantly inhibits cell proliferation and invasion in of CRC cells. To further determine the role of EphB3 in cell invasion, we used EphB3 siRNA for knockdown of EphB3 expression in HCT116 and SW620 cells, and the efficacy was confirmed by quantitative PCR and western blot analysis. Quantitative PCR analysis (Fig. 4a) and western blotting (Fig. 4b,c) showed that the expression of EphB3 was decreased after siRNA transfection. Next, results from MTT assay revealed that silencing of EphB3 could lead to the decreased capacity of growth in HCT116 and SW620 cells (Fig. 4d). In addition, transwell assay suggested that invasiveness of cells transfected with siRNA EphB3 was decreased compared to cells transfected with siRNA-NC (Fig. 4e,f). These results clearly indicated that silencing of EphB3 mimics the effects of miR-149 overexpression on malignant phenotypes of CRC cells.

Ectopic expression of EphB3 restores the phenotypes of CRC cell lines transfected with miR149. To further clarify whether miR-149 related phenotype could explain by down-regulation of EphB3, HCT116 cells were co-transfection with miR149 mimics and pEGFP/EphB3 vector. Forty-eight hour after co-transfection, quantitative RT-PCR and western blotting assays were carried out to determine the expression of EphB3.
mRNA and protein, and results exhibited that the co-transfection could rescue the decreased expression of EphB3 mRNA and protein in HCT116 cells induced by miR-149 mimics (Fig. 5a–c). We found that overexpression of EphB3 could reverse the growth inhibition in HCT116 cells induced by miR-149 mimics (Fig. 5d). Moreover, as shown in Figure 5(e–h), the decreased capacity of colony-formation and invasion in HCT116 cells induced in miR-149 mimics were also reversed through overexpression of EphB3. Taken together, these findings suggested that EphB3 was a functional target of miR-149 in CRC cells.

Silencing of EphB3 significantly affects cycle progression distribution and increases apoptosis in CRC cell lines. To explore the functional effect of EphB3 on cell cycle progression and cell survival, we measured cycle progression distribution and apoptosis in CRC cells transfected with EphB3 or a SiRNA control. Results from flow cytometry indicated that inhibition of EphB3 expression increased number of G1 and S phase cells and decreased G2 and M phase cells compared to control group cells (Fig. 6a–c). Furthermore, we detected that knockdown of EphB3 increased apoptosis in CRC cell lines measured by flow cytometry analysis (Fig. 7a,b).

To confirm the reliability of apoptosis result, we performed quantitative RT-PCR and western blotting analysis of a set of markers for apoptosis, including bcl-2, bax, caspase-3 and caspase-6. We found that a strong increase in the expression of
bcl-2, caspase-3 and caspase-6, in contrast, a strong decrease in the expression of bax in EphB3 SiRNA group compared with control group (Fig. 8a–e). In addition, the expression of cleaved caspase-3 and cleaved caspase-6 were also determined through western blotting analysis. The data revealed that the expression of cleaved caspase-3 and cleaved caspase-6 were strongly increased in EphB3 SiRNA group compared with control group (Fig. S3).

Knockdown of EphB3 inhibits tumor growth in vivo. To examine the role of EphB3 in tumor development, we constructed a BALB/C nude xenograft mouse model in which mice were transplanted with EphB3 SiRNA and EphB3-control transfected CRC cells. After 4 weeks, tumors from SiRNA EphB3 group were significantly smaller than those from mice transfected with control (Fig. 9a). Furthermore, silencing of EphB3 significantly reduced xenograft tumor volume (Fig. 9b) and tumor weight (Fig. 9c).

Discussion
Increasing evidence suggests that miRNAs play a critical role in carcinogenesis and cancer progression. Individual miRNAs have been assigned oncogenic and tumor suppressor functions, and aberrant miRNA expression has been implicated in many malignancies, including colorectal cancer. Profiling and functional studies demonstrated that many miRNAs’ potential novel prognostic values in colorectal cancer.

Previous researches have shown that the role of miR-149 was different in the progression of different types of tumors. The expression patterns of miR-149 and its target genes were various in different types of tumors. Ying et al. reported that miR-149 was a tumor suppressor and its expression was decreased in human gastric cancer. Moreover, ectopic expression of miR-149 in gastric cancer cells inhibits proliferation and cell cycle progression by downregulating target gene ZBTB2, a potent repressor of the ARF-HDM2-p53-p21 pathway. In prostate cancer, miR-149 expression was downregulated and was part of a six member diagnostic marker set that discriminated between malignant and normal tissues in prostate cancer patients. In contrast, the deletion of miR-149 leads to the lysyl oxidase oncoproteins gain of function in clear cell renal cell carcinoma. To date, little is known about the role of miR-149 in CRC. Here, we reported that miR-149 expression was significantly reduced in CRC HCT116 and SW620 cells lines. Ectopic expression of miR-149 inhibits cells migration and invasion in CRC cells. Furthermore, we also verified that EphB3 was a direct target gene of miR-149 in CRC cells.

EphB3, one of Eph transmembrane tyrosine kinase receptors, play important roles in various of tumorigenesis. Schmid et al. documented that overexpression of EphB3 and promoted tumor metastasis by enhancing cell survival and migration in non-small-cell lung cancer. Ricard et al. identified ephrinB3 as a negative regulator of cell proliferation and positive regulator of cell survival in the adult rodent brain. These findings demonstrate a crucial function for ephrinB3 in tumor progression. Our data show that EphB3 was a direct target gene of miR-149 and regulated cell development progress, including cell proliferation, invasion, cell cycle, and cell apoptosis by enhancing or knocking-down EphB3 expression.

In summary, our data indicated that miR-149 may function as a tumor suppressor in CRC HCT116 and SW620 cells lines by targeting EphB3. Therefore, downregulation of miR-149 promoted CRC cell proliferation and cell invasion, and silencing of EphB3 significantly reduced cell invasiveness, affected cell cycle progression distribution and increased apoptosis in CRC cells. Moreover, our results showed that EphB3 may function as an oncogene in the development of colorectal cancer.
Therefore, miR-149 may serve as a therapeutic target for colorectal cancer treatment. However, due to the fact that each miRNA may regulate many target genes which can affect carcinogenesis in different ways, more detailed molecular and cellular mechanisms underlying the action of miR-149 targets are needed to investigate. In addition, miR-149 might be derived from host cells in tumor micro-environment, more cautious researches are indispensable to further assess the effect of EphB3 on tumor growth in vivo.

Acknowledgments
This work was supported by Guangdong province science and technology plan projects (No. 20150119), and Chinese National Foundation of National Science Grants (No. 81402501).

Disclosure Statement
None declared.

References
1. Zhang B, Pan X, Cobb GP et al. microRNAs as oncogenes and tumor suppressors. Dev Biol 2007; 302: 1–12.
2. Lewis BP, Shih IH, Jones RMW et al. Prediction of mammalian microRNA targets. Cell 2003; 115: 787–98.
3. Davidson MR, Larsen JE, Yang IA. MicroRNA-218 is deleted and downregulated in lung squamous cell carcinoma. PLoS ONE 2010; 5: e12560.
4. Wu ZS, Wu Q, Wang CQ et al. miR-340 inhibition of breast cancer cell migration and invasion through targeting of oncoprotein c-Met. Cancer 2011; 1: 2842–52.
5. Asangani A, Rasheed AK, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdc4d and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128–36.
6. Charlotte HM, Bryan P, Arthur MM. miR-10b Targets Tiaml1 implication for Rac activation and carcinoma migration. The Journal of Biological Chemistry 2010; 285: 20541–6.
7. Huang Q, Kiranmai G, Mariette S et al. The microRNAs mir-373 and mir-520 promote tumor invasion and metastasis. Nat Cell Biol 2008; 2: 202–10.
8. Center MM, Jemal A, Smith RA et al. Worldwide variations in colorectal cancer. A Cancer Journal for Clinicians 2009; 59: 366–78.
9. Edwards BK, Ward E, Kohler BA. Annual report to the nation on the status of cancer, 1975–2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer 2010; 116: 544–73.
10. Suff JJ, Lau YJ, Goh KL et al. Increasing incidence of colorectal cancer in Asia: implications for screening. Lancet Oncol 2005; 6: 871–6.
11. Lin RJ, Lin YC, Yu AL. miR-149 induces apoptosis by inhibiting Akt1 and E2F1 in human cancer cells. Mol Cancer 2010; 19: 219–27.
12. Lin J, Hu WL, Jiang CC et al. MicroRNA-149, a p53-responsive microRNA functions as an oncogenic regulator in human melanoma. Proc Natl Acad Sci USA 2011; 108: 15840–5.
13. Liu H, Brannon AR, Reddy AR et al. Identifying microRNA targets of microRNA dysregulation in colorectal cancer, with application to clear cell RenalCell Carcinoma. BMC Syst Biol 2010; 27: 5–7.
14. Schaefer A, Jung M, Mollenkopf HJ et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer 2010; 126: 1166–76.
15. Luo Z, Zhang L, Li Z et al. An in silico analysis of dynamic changes in microRNA expression profiles in stepwise development of nasopharyngeal carcinoma. BMC Med Genomics 2012; 19: 3–14.
16. Wang Y, Zhang XS, Zhang ZY et al. MicroRNA-149 inhibits proliferation and cell cycle progression through the targeting of ZBTB2 in human gastric cancer. PLoS ONE 2012; 7: e41058.

Supporting Information
Additional Supporting Information may be found online in the supporting information tab for this article:
Fig. S1. Construction of luciferase reporter vector. (a) Amplification of full length EphB3 3’UTR. (b) Verification of luciferase reporter vector construction by double digestion.

Fig. S2. miR-149 relative expression level transfected with different concentration of miR-149 mimics in CRC cell.

Fig. S3. Western blots analysis of cleaved caspase-3 and cleaved caspase-6 expression in CRC cells transfected with SiEphB3 or a SiRNA control.